Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12620001331921
Ethics application status
Approved
Date submitted
27/10/2020
Date registered
10/12/2020
Date last updated
7/04/2024
Date data sharing statement initially provided
10/12/2020
Date results information initially provided
7/04/2024
Type of registration
Prospectively registered
Titles & IDs
Public title
Effects of a herbal supplement on cognition and social behaviour in healthy adults.
Query!
Scientific title
Neurocognitive effects of a multiherbal, polyphenol rich supplement for cognition and prosocial behaviour in healthy adults: a randomised controlled trial.
Query!
Secondary ID [1]
301953
0
Nil
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
HrBI2
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Healthy adults cognitive function and self reported behaviour
318509
0
Query!
Condition category
Condition code
Mental Health
316515
316515
0
0
Query!
Studies of normal psychology, cognitive function and behaviour
Query!
Alternative and Complementary Medicine
316517
316517
0
0
Query!
Other alternative and complementary medicine
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
A 6 week, double blinded, placebo-controlled between conditions (active and placebo supplementation) intervention, which includes 4 weeks of supplementation followed by 2-weeks washout. Participants consume a single, 2 tablet dose (500 mg) daily for 4 weeks of the either the active supplement (herbal combination of Bacopa 300mg, Ginseng 100mg and Coffee fruit extract 100mg) or placebo (microcrystalline cellulose 581mg), followed by 2 weeks (14 days ) of no supplement. Participants will complete three testing points, pre intervention, post supplementation and post wash-out. Adherence will be measured through participant self report and by checking remaining supplement tablets at the post intervention testing session.
Query!
Intervention code [1]
318243
0
Treatment: Other
Query!
Comparator / control treatment
Placebo (microcrystalline cellulose 581mg)
Query!
Control group
Placebo
Query!
Outcomes
Primary outcome [1]
324652
0
As a composite primary outcome, a cognitive test battery includes tasks of working memory ( N-back) and attention ( choice reaction time and Stroop). Overall, response time and accuracy scores will be used to provide an estimate of better or worse performance in relation to speed of response post intervention,
Query!
Assessment method [1]
324652
0
Query!
Timepoint [1]
324652
0
End of the supplementation and end of 2 weeks washout.
Participants will complete a post intervention assessment after the 4 weeks of supplementation and then again after 2 weeks washout, compared to baseline.
Query!
Primary outcome [2]
325872
0
Mood outcome will be assessed through self report, validated questionnaire of depression, anxiety and stress scale ( DASS21). The overall sub scale scores and change from baseline scores will be used.
Query!
Assessment method [2]
325872
0
Query!
Timepoint [2]
325872
0
End of the supplementation and end of 2 weeks washout.
Participants will complete a post intervention assessment after the 4 weeks of supplementation and then again after 2 weeks washout, compared to baseline.
Query!
Primary outcome [3]
325904
0
Pro-social behaviour composite outcome will be assessed through self report, validated questionnaires that include adult prosociality scale (APS) social safeness scale (SS). The overall score and change from baseline scores will be used.
Query!
Assessment method [3]
325904
0
Query!
Timepoint [3]
325904
0
End of the supplementation and end of 2 weeks washout.
Participants will complete a post intervention assessment after the 4 weeks of supplementation and then again after 2 weeks washout, compared to baseline.
Query!
Secondary outcome [1]
385341
0
Brain activation through fNIRS ( functional near-infrared spectroscopy) measured during task performance at the three testing sessions ( pre intervention post intervention, and post washout).
Query!
Assessment method [1]
385341
0
Query!
Timepoint [1]
385341
0
End of the supplementation and end of 2 weeks washout.
Participants will complete a post intervention assessment after the 4 weeks of supplementation and then again after 2 weeks washout, compared to baseline.
Query!
Secondary outcome [2]
385342
0
Brain derived neurotrophic factor (BDNF) - an important protein related to nervous system function will be assessed through blood sample.
Query!
Assessment method [2]
385342
0
Query!
Timepoint [2]
385342
0
End of the supplementation and end of 2 weeks washout.
Participants will complete a post intervention assessment after the 4 weeks of supplementation and then again after 2 weeks washout, compared to baseline.
Query!
Secondary outcome [3]
389723
0
As a further primary mood outcome, a measure of compassion for self and others (fears of compassion scale FCS) will be used as a self report, validated questionnaire The overall sub scale scores and change from baseline scores will be used.
Query!
Assessment method [3]
389723
0
Query!
Timepoint [3]
389723
0
End of the supplementation and end of 2 weeks washout.
Participants will complete a post intervention assessment after the 4 weeks of supplementation and then again after 2 weeks washout, compared to baseline.
Query!
Eligibility
Key inclusion criteria
Healthy adults aged 35- 65 years, without major medical conditions, such as diabetes,
cardiovascular disease, acute or terminal illness; BMI below 35, moderate alcohol consumption, no medication changes for the management of
health conditions within last 6 weeks, no current or recent history of taking medications for mood disorders and/or previous history of neurological conditions as these conditions have been shown to be related to impaired cognitive performance.
Query!
Minimum age
35
Years
Query!
Query!
Maximum age
65
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
Yes
Query!
Key exclusion criteria
Pre-existing medical conditions, including diabetes, cardiovascular disease, medication changes for the management of health conditions within last 6 weeks, current or recent history of taking medications for mood disorders and/or previous history of neurological conditions.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Yes - supplements will be in numbered containers and allocation involves contacting the holder of the
allocation schedule to determine which number container is to be randomly allocated to the participant.
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Simple randomisation using a randomisation schedule created by computer software (i.e. computerised sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Not Applicable
Query!
Type of endpoint/s
Efficacy
Query!
Statistical methods / analysis
Based on sample size calculation from previous studies assessing cognitive changes and fNIRS changes, a minimum of 80 participants (40/group) is required to provide 80% power to detect a 20% change in cognitive -behavioural measures, assuming a standard deviation of 10-20% for outcome measures at an alpha level of 0.05. However, it is proposed that 110 participants be recruited to account for a 20-30% attrition rate of participants during a 4week intervention period. Change from baseline measures with ANOVA will be used to examine between group differences.
Query!
Recruitment
Recruitment status
Completed
Query!
Date of first participant enrolment
Anticipated
11/01/2021
Query!
Actual
8/04/2021
Query!
Date of last participant enrolment
Anticipated
1/11/2021
Query!
Actual
9/11/2021
Query!
Date of last data collection
Anticipated
31/12/2021
Query!
Actual
21/12/2021
Query!
Sample size
Target
80
Query!
Accrual to date
Query!
Final
60
Query!
Recruitment in Australia
Recruitment state(s)
QLD
Query!
Funding & Sponsors
Funding source category [1]
306379
0
Commercial sector/Industry
Query!
Name [1]
306379
0
USANA Health Sciences Inc
Query!
Address [1]
306379
0
3838 West Parkway Boulevard
Salt Lake City, UT 84120
Query!
Country [1]
306379
0
United States of America
Query!
Primary sponsor type
University
Query!
Name
Central Queensland University
Query!
Address
160 Ann Street Brisbane, QLD Australia 4000
Query!
Country
Australia
Query!
Secondary sponsor category [1]
306881
0
University
Query!
Name [1]
306881
0
Nanyang Technological University
Query!
Address [1]
306881
0
50 Nanyang Avenue, Singapore 639798
Query!
Country [1]
306881
0
Singapore
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
306576
0
Human Research Ethics Committee Central Queensland University
Query!
Ethics committee address [1]
306576
0
554-700 Yaamba Rd, Norman Gardens QLD 4701
Query!
Ethics committee country [1]
306576
0
Australia
Query!
Date submitted for ethics approval [1]
306576
0
29/06/2020
Query!
Approval date [1]
306576
0
16/09/2020
Query!
Ethics approval number [1]
306576
0
0000022500
Query!
Summary
Brief summary
Evidence from scientifc studies demonstrate positive effects of ingredients Ginseng (Cereboost), Bacopa and Coffee fruit extract as isolated components, on various mechanisms that impact cognitive performance and mood. For example, Ginseng
and Gingko have been shown to enhance cognitive performance after acute dosing whilst Bacopa has been shown to have effects primarily with chronic dosing. To date however, the effect of these combined ingredients on cognition, behaviour and brain functioning as a result of chronic dosing has not been evaluated.
The study involves a four-week supplementation period followed by a two-week washout period. Measures of cognitive performance, behaviour, and BDNF levels are undertaken at baseline (presupplementation), postsupplementation (week 4) and at the end of the washout period (week 6) to assess potential supplementation effects on cognitive performance and functioning. This research seeks to understand any changes in cognitive performance and brain activation patterns using standardized cognitive tasks and a non-invasive functional near infrared spectroscopy (fNIRS), measured both before and after taking the active or placebo supplement.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
104342
0
A/Prof Talitha Best
Query!
Address
104342
0
School of Health, Medical and Applied Science
Central Queensland University
160 Ann street, Brisbane QLD 4000
Query!
Country
104342
0
Australia
Query!
Phone
104342
0
+61732951131
Query!
Fax
104342
0
Query!
Email
104342
0
[email protected]
Query!
Contact person for public queries
Name
104343
0
A/Prof Talitha Best
Query!
Address
104343
0
School of Health, Medical and Applied Science
Central Queensland University
160 Ann street, Brisbane QLD 4000
Query!
Country
104343
0
Australia
Query!
Phone
104343
0
+61732951131
Query!
Fax
104343
0
Query!
Email
104343
0
[email protected]
Query!
Contact person for scientific queries
Name
104344
0
A/Prof Talitha Best
Query!
Address
104344
0
School of Health, Medical and Applied Science
Central Queensland University
160 Ann street, Brisbane QLD 4000
Query!
Country
104344
0
Australia
Query!
Phone
104344
0
+61732951131
Query!
Fax
104344
0
Query!
Email
104344
0
[email protected]
Query!
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
Query!
What data in particular will be shared?
De-identified individual participant data underlying published results only.
Query!
When will data be available (start and end dates)?
Following main results publication up to 12 months.
Query!
Available to whom?
only researchers who provide a methodologically sound proposal, case-by-case basis.
Query!
Available for what types of analyses?
Decided upon relevant request regarding meta analyses or in line with approved aims/intention of the study
Query!
How or where can data be obtained?
Access subject to approval by Principal Investigator, email:
[email protected]
or phone +61 7 3295 1131
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF